MCID: LNG039
MIFTS: 57

Lung Squamous Cell Carcinoma

Categories: Cancer diseases, Respiratory diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lung Squamous Cell Carcinoma

MalaCards integrated aliases for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 11 14
Squamous Cell Carcinoma of Lung 11 71
Squamous Cell Lung Carcinoma 5 16
Epidermoid Cell Carcinoma of the Lung 11
Squamous Cell Lung Cancer 53

Classifications:



External Ids:

Disease Ontology 11 DOID:3907
NCIt 49 C3493
SNOMED-CT 68 254634000
UMLS 71 C0149782

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology: 11 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary: Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to squamous cell carcinoma and lung cancer susceptibility 3. An important gene associated with Lung Squamous Cell Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs Afatinib and Nedaplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and lymph node, and related phenotype is Decreased viability.

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 522)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.9 TUG1 TP53 SOX2-OT PIK3CA NFE2L2 KRAS
2 lung cancer susceptibility 3 32.3 TUG1 TP53 SFTA1P PIK3CA NPTN-IT1 NFE2L2
3 adenocarcinoma 32.3 TP53 PIK3CA KRAS HRAS EGFR
4 lung cancer 32.0 TUG1 TP53 TERC SOX2-OT SNHG1 PVT1
5 small cell cancer of the lung 31.9 TUG1 TP53 PIK3CA EGFR CCAT2
6 lung benign neoplasm 31.6 TP53 KRAS HRAS EGFR
7 retinitis pigmentosa 11 31.4 TUG1 TP53 SOX2-OT PVT1 EGFR CCAT2
8 squamous cell carcinoma, head and neck 31.4 TP53 PIK3CA NFE2L2 HRAS EGFR
9 keratinizing squamous cell carcinoma 31.3 TP53 PIK3CA HRAS EGFR
10 large cell carcinoma 31.2 TP53 KRAS HRAS EGFR
11 exanthem 31.1 KRAS HRAS EGFR
12 esophagus squamous cell carcinoma 30.9 TUG1 SNHG1 PVT1 NPTN-IT1 MEG3 EGFR
13 esophageal cancer 30.9 TP53 PVT1 PIK3CA MEG3 KRAS HRAS
14 pleomorphic carcinoma 30.9 TP53 KRAS HRAS EGFR
15 papillary adenocarcinoma 30.9 TP53 KRAS HRAS
16 adenoma 30.8 TP53 PIK3CA KRAS HRAS
17 lung carcinoma in situ 30.8 TP53 KRAS HRAS EGFR
18 rectal benign neoplasm 30.8 TP53 PIK3CA KRAS HRAS EGFR
19 signet ring cell adenocarcinoma 30.8 TP53 KRAS HRAS
20 large cell neuroendocrine carcinoma 30.8 TP53 KRAS HRAS EGFR
21 lung adenoma 30.8 TP53 KRAS HRAS EGFR
22 rectum adenocarcinoma 30.8 TP53 PIK3CA KRAS HRAS EGFR
23 colorectal adenocarcinoma 30.8 TP53 PIK3CA KRAS HRAS EGFR
24 breast adenocarcinoma 30.8 TP53 PIK3CA KRAS HRAS EGFR
25 bronchiolo-alveolar adenocarcinoma 30.8 TP53 KRAS HRAS EGFR
26 colonic benign neoplasm 30.8 TP53 PIK3CA KRAS HRAS EGFR
27 lung sarcomatoid carcinoma 30.8 KRAS HRAS EGFR
28 laryngeal benign neoplasm 30.8 TP53 PIK3CA EGFR
29 gastrointestinal stromal tumor 30.8 TP53 PIK3CA KRAS HRAS EGFR
30 skin melanoma 30.8 TP53 PIK3CA KRAS HRAS
31 adenoid cystic carcinoma 30.8 TP53 PIK3CA KRAS HRAS EGFR
32 lung non-squamous non-small cell carcinoma 30.8 KRAS HRAS EGFR
33 thyroid gland anaplastic carcinoma 30.8 TP53 PIK3CA HRAS EGFR
34 head and neck cancer 30.8 TP53 PIK3CA KRAS HRAS EGFR
35 skin squamous cell carcinoma 30.8 TP53 HRAS EGFR
36 rectum cancer 30.8 TP53 KRAS HRAS EGFR
37 pleomorphic rhabdomyosarcoma 30.8 TP53 PIK3CA HRAS
38 cholangiocarcinoma 30.8 TUG1 TP53 SOX2-OT PIK3CA KRAS EGFR
39 malignant pleural mesothelioma 30.8 TP53 PVT1 HRAS EGFR
40 kidney cancer 30.8 TP53 PVT1 PIK3CA MEG3 EGFR
41 colon adenocarcinoma 30.8 TP53 PIK3CA KRAS HRAS EGFR
42 diffuse gastric cancer 30.8 TP53 PIK3CA KRAS
43 intrahepatic cholangiocarcinoma 30.8 TUG1 TP53 KRAS HRAS EGFR CCAT2
44 gastric adenocarcinoma 30.8 TP53 PIK3CA KRAS HRAS
45 wilms tumor 1 30.8 TP53 MEG3 KRAS HRAS EGFR
46 glioma 30.8 TP53 PVT1 PIK3CA MEG3 EGFR CCAT2
47 glioblastoma 30.8 TUG1 TP53 PIK3CA MEG3 KRAS HRAS
48 neuroblastoma 30.7 TP53 SNHG1 PIK3CA NFE2L2 MEG3 HRAS
49 rhabdomyosarcoma 30.7 TP53 PIK3CA KRAS HRAS EGFR
50 nasopharyngeal carcinoma 30.7 TP53 PVT1 PIK3CA NPTN-IT1 MEG3 EGFR

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

25 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.68 EGFR HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 9.68 EGFR HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 9.68 KRAS
4 Decreased viability GR00106-A-0 9.68 KRAS
5 Decreased viability GR00221-A-1 9.68 EGFR HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-2 9.68 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 9.68 HRAS
8 Decreased viability GR00221-A-4 9.68 EGFR PIK3CA
9 Decreased viability GR00301-A 9.68 KRAS
10 Decreased viability GR00381-A-1 9.68 KRAS
11 Decreased viability GR00402-S-2 9.68 PIK3CA

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Afatinib Approved Phase 4 439081-18-2, 850140-72-6 53445376 10184653
2
Nedaplatin Approved, Investigational Phase 4 95734-82-0
3
Rivoceranib Investigational Phase 4 811803-05-1 11315474
4
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
5
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
6
Palbociclib Approved, Investigational Phase 2, Phase 3 571190-30-2 5330286
7
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
8
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
9
Bevacizumab Approved, Investigational Phase 3 216974-75-3 135329020
10
Ipilimumab Approved Phase 3 477202-00-9
11
Cetuximab Approved Phase 3 205923-56-4
12
Erlotinib Approved, Investigational Phase 2, Phase 3 183319-69-9, 183321-74-6 176870
13
Iniparib Investigational Phase 3 160003-66-7 9796068
14
Rilotumumab Investigational Phase 2, Phase 3 872514-65-3
15 Endostar protein Phase 3
16 Endostatins Phase 3
17 Antimetabolites Phase 3
18 Poly(ADP-ribose) Polymerase Inhibitors Phase 3
19 Shark Cartilage Phase 3
20 Angiogenesis Inhibitors Phase 3
21 Immunoglobulin G Phase 3
22 Endothelial Growth Factors Phase 3
23 Mitogens Phase 3
24 Antineoplastic Agents, Immunological Phase 2, Phase 3
25 Protein Kinase Inhibitors Phase 2, Phase 3
26 Immunoglobulins, Intravenous Phase 2, Phase 3
27 Immunoglobulins Phase 2, Phase 3
28 Antibodies, Monoclonal Phase 2, Phase 3
29 Antibodies Phase 2, Phase 3
30
Treosulfan Approved, Investigational Phase 2 299-75-2 9296
31
Clarithromycin Approved Phase 2 81103-11-9 84029
32
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
33
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
34
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
35
Tremelimumab Approved, Investigational Phase 2 745013-59-6
36
Ceritinib Approved Phase 2 1032900-25-6 57379345
37
Nintedanib Approved Phase 2 656247-17-5 135423438 9809715
38
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
39
Auranofin Approved, Investigational Phase 1, Phase 2 34031-32-8 6918453 16667669 70788951
40
Lenograstim Approved, Investigational Phase 2 135968-09-1
41
Picropodophyllin Approved, Investigational Phase 2 518-28-5, 477-47-4 10607 72435
42
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
43
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
44
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4 254741536
45
Fludarabine Approved Phase 1, Phase 2 75607-67-9, 21679-14-1 30751 657237
46
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
47
Aldesleukin Approved Phase 1, Phase 2 110942-02-4
48
Coenzyme M Approved, Investigational Phase 1, Phase 2 3375-50-6 598 23662354
49
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
50
Cisplatin Approved Phase 2 15663-27-1 2767 5702198 441203

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Apatinib Mesylate Was Used in the Treament of Patients With Advanced Lung Squamous Cell Carcinoma of the Third Line and Above Unknown status NCT03725423 Phase 4 Apatinib
2 An Open-label, Single-arm Clinical Study to Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation Unknown status NCT04132102 Phase 4 Afatinib
3 Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study Completed NCT02088515 Phase 4 Nedaplatin;Cisplatin;Docetaxel
4 Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3 Intravenous Cisplatin & etoposide;Intravenous Cisplatin & etoposide along with oral cyclophosphamide
5 The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration. Unknown status NCT02283476 Phase 3 Endostar continuous intravenous infusion;Endostar routine intravenous infusion;Gemcitabine;Cisplatin
6 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase Ⅲ Study Unknown status NCT02643407 Phase 3 Docetaxel;Nedaplatin;Cisplatin
7 A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Paclitaxel vs Placebo Combined With Carboplatin and Paclitaxel as First-line Therapy in Patients With Metastatic Squamous Non-small Cell Lung Cancer Unknown status NCT03866993 Phase 3 Paclitaxel;Carboplatin;Placebo
8 A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study) Completed NCT02766335 Phase 2, Phase 3 Docetaxel
9 A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Completed NCT02965378 Phase 2, Phase 3 Docetaxel;FGFR Inhibitor AZD4547
10 A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Completed NCT02785939 Phase 2, Phase 3 Docetaxel;Palbociclib
11 A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
12 Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
13 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
14 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
15 Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3 gemcitabine/carboplatin;gemcitabine/carboplatin plus Iniparib
16 A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study) Active, not recruiting NCT02785952 Phase 3
17 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
18 Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3) Active, not recruiting NCT03150875 Phase 3 IBI308;Docetaxel
19 A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Terminated NCT02926638 Phase 2, Phase 3 Erlotinib Hydrochloride
20 Photodynamic Therapy for the Prevention of Lung Cancer (PEARL) Withdrawn NCT03346304 Phase 2, Phase 3
21 An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer Unknown status NCT02009605 Phase 2 Icotinib
22 A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy Unknown status NCT01969955 Phase 2 nanoparticle albumin-bound paclitaxel
23 Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial Unknown status NCT01660399 Phase 2 Boanmycin;Docetaxel
24 Phase II Study of Afatinib Plus Chemotherapy in Patients With Esophageal and Lung Squamous Cell Carcinoma Unknown status NCT03486509 Phase 2 Afatinib
25 A Multicenter Phase II Trial of Induction Nimotuzumab Plus Gemcitabine and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Squamous Cell Lung Carcinoma Unknown status NCT02428764 Phase 2 Nimotuzumab;Gemcitabine;Carboplatin
26 A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers Unknown status NCT02583542 Phase 1, Phase 2 AZD2014;AZD6244
27 A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, Respectively After Platin Failure Unknown status NCT02852083 Phase 2 Pioglitazone;nivolumab;Treosulfan;Clarithromycin
28 SQUINT (Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) Unknown status NCT03823625 Phase 2 Nivolumab plus Ipilimumab;Platinum-based chemotherapy plus Nivolumab
29 A Phase II Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Docetaxel Consolidation in Patients With Inoperable Stage IIIA/B Squamous Cell Lung Cancer Unknown status NCT02787473 Phase 2 pemetrexed;cisplatin;docetaxel
30 A Phase II Study of Concurrent Nab-Paclitaxel, Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer Unknown status NCT01494415 Phase 2 Paclitaxel for Injection(Albumin Bound);carboplatin
31 A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Squamous Non Small Cell Lung Carcinoma (sqNSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy. Unknown status NCT03827850 Phase 2 ERDAFITINIB
32 A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers Unknown status NCT02423590 Phase 2 Apatorsen (OGX-427);Gemcitabine;Carboplatin
33 A Randomized Phase II Clinical Trial of Nab-Paclitaxel and Carboplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung Completed NCT01236716 Phase 2 Albumin paclitaxel plus carboplatin;Gemcitabine plus carboplatin
34 A Phase 2 Study of MLN0128 (TAK-228) in Patients With Advanced Non-Small Cell Lung Cancers Harboring NFE2L2 and KEAP1 Mutations Completed NCT02417701 Phase 2 Sapanisertib
35 A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
36 A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) Completed NCT02785913 Phase 2 Taselisib
37 A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) Completed NCT03377556 Phase 2 Talazoparib
38 A Phase II Study of ABBV-399 in Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY) Completed NCT03574753 Phase 2 ABBV-399
39 A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study) Completed NCT03373760 Phase 2
40 A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Completed NCT02276027 Phase 2 BYL719;INC280;LDK378;MEK162
41 Phase II Trial of the Akt Inhibitor MK-2206 Plus Erlotinib (OSI-774) in Patients With Advanced Non-small Cell Lung Cancer Who Have Progressed After Previous Response (Including Stable Disease) With Erlotinib Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
42 A Phase II Trial of TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Carcinoma of the Lung Completed NCT02920476 Phase 2 TAS-102
43 A Prospective Randomized Phase Ⅱ Study of Nimotuzumab Combined With Chemoradiotherapy for Unresectable, Locally Advanced Squamous Cell Lung Cancer Completed NCT02577341 Phase 2 Nimotuzumab;docetaxel and cisplatin
44 FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens Completed NCT01948141 Phase 2 nintedanib
45 AVF4236s: Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer Completed NCT00585377 Phase 2 Bevacizumab and Erlotinib
46 A Phase II Study of Prophylactic Radiation Therapy for the Prevention of Hemoptysis in Advanced Non Small Cell Lung Cancer in Combination With Bevacizumab, Paclitaxel, and Carboplatin in Patients at High Risk for Bevacizumab-Associated Hemoptysis Completed NCT00387374 Phase 2 paclitaxel;carboplatin
47 Phase II Trial of OSI-774 (NSC-718781) in Patients With Advanced Non-Small Cell Lung Cancer and a Performance Status of 2 Completed NCT00087412 Phase 2 erlotinib hydrochloride
48 A Phase II Trial of Combination Carboplatin, Paclitaxel, Cetuximab and Bevacizumab (NSC-704865) Followed By Cetuximab and Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
49 ZD1839 (NSC #715055, IND #61187) With Induction Paclitaxel And Carboplatin Followed By Either Radiation Or Concomitant Radiation With Weekly Paclitaxel And Carboplatin In Stage III Non-Small Cell Lung Cancer, A Phase II Study Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
50 A Phase II Trial of Docetaxel Plus Cetuximab and Docetaxel Plus Bortezomib (NSC #681239, IND #58443) in Advanced Non-Small Cell Lung Cancer Patients With Performance Status (PS) 2 Completed NCT00118183 Phase 2 docetaxel;bortezomib

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Genetic Tests for Lung Squamous Cell Carcinoma

Anatomical Context for Lung Squamous Cell Carcinoma

Organs/tissues related to Lung Squamous Cell Carcinoma:

MalaCards : Lung, T Cells, Lymph Node, Endothelial, Bone Marrow, Brain, Bronchial Epithelium

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 3543)
# Title Authors PMID Year
1
Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. 62 5
23786770 2013
2
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. 62 5
22328973 2011
3
EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. 62 5
20360610 2010
4
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. 62 5
6695174 1984
5
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
6
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. 5
23102728 2013
7
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. 5
22753918 2012
8
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma. 5
20942962 2010
9
LKB1 modulates lung cancer differentiation and metastasis. 5
17676035 2007
10
Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. 5
15800014 2005
11
[The evaluation of prognostic value of cyclin B1 expression in patients with resected non-small-cell lung cancer stage I-IIIA--preliminary report]. 53 62
20369739 2010
12
Metabolic targets of cardiac hormones' therapeutic anti-cancer effects. 53 62
20030620 2010
13
Cardiac and renal hormones: anticancer effects in vitro and in vivo. 53 62
19092678 2009
14
[The prognostic value of cytokeratin 19 expression in non-small cell lung cancer]. 53 62
18080980 2007
15
[Transcription TIMP3, DAPk1 and AKR1B10 genes in squamous cell lung cancer]. 53 62
17209433 2006
16
Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer? 53 62
16487258 2006
17
Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. 53 62
15893003 2005
18
Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. 53 62
11277326 2000
19
Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. 53 62
9291807 1997
20
Production of cytokeratin 19 fragment by human squamous lung cancer cell lines. 53 62
9160842 1997
21
A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma. 53 62
8882476 1996
22
Serum tumor marker CYFRA 21-1 in the diagnostics of squamous cell lung cancer--comparison with CEA. 53 62
8841502 1996
23
Clinical evaluation of CYFRA 21-1 in malignant pleural fluids. 53 62
7536317 1995
24
Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. 53 62
8069601 1993
25
Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer. 53 62
2361475 1990
26
Histological types of lung cancer attributable to fine particulate, smoking, and genetic susceptibility. 62
36334679 2023
27
Pan-cancer analysis of Chromobox (CBX) genes for prognostic significance and cancer classification. 62
36183965 2023
28
The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer. 62
36456139 2022
29
PPARgamma agonism inhibits progression of premalignant lesions in a murine lung squamous cell carcinoma model. 62
35830207 2022
30
Diet-wide association study of 92 foods and nutrients and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study. 62
35830197 2022
31
A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer. 62
36464708 2022
32
Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302. 62
36241930 2022
33
Efficacy of direct oral anticoagulant for renal infarction due to pulmonary vein stump thrombosis after left pneumonectomy. 62
36459304 2022
34
Influence of ABO blood group on susceptibility to different pathological types of lung cancer: a retrospective study. 62
36464709 2022
35
Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients. 62
36456645 2022
36
Construction of a prognostic model for lung squamous cell carcinoma based on immune-related genes. 62
36455238 2022
37
Dysregulated Th1 cells in lung squamous cell carcinoma. 62
35686499 2022
38
FDG PET/CT in Isolated Nasal Cavity Metastasis From Squamous Cell Lung Cancer. 62
35961364 2022
39
Natural history of lung squamous cell brain metastases in patients treated with radiosurgery: a thirty-year experience at a tertiary medical center. 62
36469189 2022
40
Novel blood-based FUT7 DNA methylation is associated with lung cancer: especially for lung squamous cell carcinoma. 62
36463240 2022
41
Co-occurring KEAP1 and TP53 mutations in lung squamous cell carcinoma induced primary resistance to thoracic radiotherapy: A case report. 62
36453575 2022
42
Solitary metachronous splenic metastasis related with lung squamous cell carcinoma: A case report. 62
36464590 2022
43
ASO Visual Abstract: S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial. 62
36209323 2022
44
S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial. 62
36097299 2022
45
ZEB1-activated Notch1 promotes circulating tumor cell migration and invasion in lung squamous cell carcinoma. 62
36418641 2022
46
Roles of H19/miR-29a-3p/COL1A1 axis in COE-induced lung cancer. 62
36150622 2022
47
Squamous cell lung cancer: Current landscape and future therapeutic options. 62
36270277 2022
48
Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer. 62
36430217 2022
49
CRISPR-mediated MECOM depletion retards tumor growth by reducing cancer stem cell properties in lung squamous cell carcinoma. 62
35733338 2022
50
Minichromosome maintenance gene family: potential therapeutic targets and prognostic biomarkers for lung squamous cell carcinoma. 62
36445337 2022

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

5 (show top 50) (show all 329)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 EGFR NM_005228.5(EGFR):c.2492G>A (p.Arg831His) SNV Pathogenic
560007 rs150036236 GRCh37: 7:55259434-55259434
GRCh38: 7:55191741-55191741
2 KRAS NM_004985.5(KRAS):c.34G>C (p.Gly12Arg) SNV Pathogenic
12579 rs121913530 GRCh37: 12:25398285-25398285
GRCh38: 12:25245351-25245351
3 TP53 NM_000546.6(TP53):c.733G>C (p.Gly245Arg) SNV Likely Pathogenic
376604 rs28934575 GRCh37: 17:7577548-7577548
GRCh38: 17:7674230-7674230
4 TP53 NM_000546.6(TP53):c.641A>G (p.His214Arg) SNV Likely Pathogenic
376615 rs1057519992 GRCh37: 17:7578208-7578208
GRCh38: 17:7674890-7674890
5 TP53 NM_000546.6(TP53):c.808T>A (p.Phe270Ile) SNV Likely Pathogenic
376596 rs1057519988 GRCh37: 17:7577130-7577130
GRCh38: 17:7673812-7673812
6 CDKN2A NM_000077.5(CDKN2A):c.239G>A (p.Arg80Gln) SNV Likely Pathogenic
376385 rs1057519883 GRCh37: 9:21971119-21971119
GRCh38: 9:21971120-21971120
7 TP53 NM_000546.6(TP53):c.841G>C (p.Asp281His) SNV Likely Pathogenic
376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
8 TP53 NM_000546.6(TP53):c.487T>C (p.Tyr163His) SNV Likely Pathogenic
376680 rs786203436 GRCh37: 17:7578443-7578443
GRCh38: 17:7675125-7675125
9 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely Pathogenic
12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
10 TP53 NM_000546.6(TP53):c.725G>A (p.Cys242Tyr) SNV Likely Pathogenic
12354 rs121912655 GRCh37: 17:7577556-7577556
GRCh38: 17:7674238-7674238
11 STK11 NM_000455.5(STK11):c.1060T>C (p.Phe354Leu) SNV Likely Pathogenic
376711 rs1057520018 GRCh37: 19:1223123-1223123
GRCh38: 19:1223124-1223124
12 TP53 NM_000546.6(TP53):c.658T>A (p.Tyr220Asn) SNV Likely Pathogenic
376688 rs530941076 GRCh37: 17:7578191-7578191
GRCh38: 17:7674873-7674873
13 TP53 NM_000546.6(TP53):c.808T>G (p.Phe270Val) SNV Likely Pathogenic
376598 rs1057519988 GRCh37: 17:7577130-7577130
GRCh38: 17:7673812-7673812
14 FGFR3 NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys) SNV Likely Pathogenic
16339 rs121913483 GRCh37: 4:1803568-1803568
GRCh38: 4:1801841-1801841
15 TP53 NM_000546.6(TP53):c.838A>G (p.Arg280Gly) SNV Likely Pathogenic
376658 rs753660142 GRCh37: 17:7577100-7577100
GRCh38: 17:7673782-7673782
16 TP53 NM_000546.6(TP53):c.536A>C (p.His179Pro) SNV Likely Pathogenic
376611 rs1057519991 GRCh37: 17:7578394-7578394
GRCh38: 17:7675076-7675076
17 TP53 NM_000546.6(TP53):c.527G>A (p.Cys176Tyr) SNV Likely Pathogenic
186451 rs786202962 GRCh37: 17:7578403-7578403
GRCh38: 17:7675085-7675085
18 TP53 NM_000546.6(TP53):c.537T>G (p.His179Gln) SNV Likely Pathogenic
376607 rs876660821 GRCh37: 17:7578393-7578393
GRCh38: 17:7675075-7675075
19 TP53 NM_000546.6(TP53):c.374C>T (p.Thr125Met) SNV Likely Pathogenic
183748 rs786201057 GRCh37: 17:7579313-7579313
GRCh38: 17:7675995-7675995
20 TP53 NM_000546.6(TP53):c.403T>G (p.Cys135Gly) SNV Likely Pathogenic
376563 rs1057519975 GRCh37: 17:7578527-7578527
GRCh38: 17:7675209-7675209
21 TP53 NM_000546.6(TP53):c.451C>A (p.Pro151Thr) SNV Likely Pathogenic
12369 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
22 TP53 NM_000546.6(TP53):c.832C>G (p.Pro278Ala) SNV Likely Pathogenic
376645 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
23 PTEN NM_000314.8(PTEN):c.389G>T (p.Arg130Leu) SNV Likely Pathogenic
376509 rs121909229 GRCh37: 10:89692905-89692905
GRCh38: 10:87933148-87933148
24 TP53 NM_000546.6(TP53):c.743G>T (p.Arg248Leu) SNV Likely Pathogenic
230253 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
25 TP53 NM_000546.6(TP53):c.584T>A (p.Ile195Asn) SNV Likely Pathogenic
376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
26 TP53 NM_000546.6(TP53):c.535C>T (p.His179Tyr) SNV Likely Pathogenic
127815 rs587780070 GRCh37: 17:7578395-7578395
GRCh38: 17:7675077-7675077
27 TP53 NM_000546.6(TP53):c.731G>A (p.Gly244Asp) SNV Likely Pathogenic
372785 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
28 TP53 NM_000546.6(TP53):c.742C>G (p.Arg248Gly) SNV Likely Pathogenic
376652 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
29 TP53 NM_000546.6(TP53):c.578A>C (p.His193Pro) SNV Likely Pathogenic
376612 rs786201838 GRCh37: 17:7578271-7578271
GRCh38: 17:7674953-7674953
30 PTPN11 NM_002834.5(PTPN11):c.227A>G (p.Glu76Gly) SNV Likely Pathogenic
13338 rs121918465 GRCh37: 12:112888211-112888211
GRCh38: 12:112450407-112450407
31 EGFR NM_005228.5(EGFR):c.2582T>C (p.Leu861Pro) SNV Likely Pathogenic
376145 rs121913444 GRCh37: 7:55259524-55259524
GRCh38: 7:55191831-55191831
32 EGFR NM_005228.5(EGFR):c.2582T>G (p.Leu861Arg) SNV Likely Pathogenic
45287 rs121913444 GRCh37: 7:55259524-55259524
GRCh38: 7:55191831-55191831
33 PPP6C NM_002721.5(PPP6C):c.790C>T (p.Arg264Cys) SNV Likely Pathogenic
376508 rs763733111 GRCh37: 9:127912080-127912080
GRCh38: 9:125149801-125149801
34 DDR2 NM_006182.4(DDR2):c.716T>G (p.Leu239Arg) SNV Likely Pathogenic
376141 rs578015216 GRCh37: 1:162729630-162729630
GRCh38: 1:162759840-162759840
35 PTPN11 NM_002834.5(PTPN11):c.227A>C (p.Glu76Ala) SNV Likely Pathogenic
13339 rs121918465 GRCh37: 12:112888211-112888211
GRCh38: 12:112450407-112450407
36 EPHA2 NM_004431.5(EPHA2):c.1171G>C (p.Gly391Arg) SNV Likely Pathogenic
376146 rs34192549 GRCh37: 1:16464489-16464489
GRCh38: 1:16137994-16137994
37 EGFR NM_005228.5(EGFR):c.2240T>C (p.Leu747Ser) SNV Likely Pathogenic
45236 rs397517097 GRCh37: 7:55242470-55242470
GRCh38: 7:55174777-55174777
38 EPHA2 NM_004431.5(EPHA2):c.1171G>A (p.Gly391Arg) SNV Likely Pathogenic
259386 rs34192549 GRCh37: 1:16464489-16464489
GRCh38: 1:16137994-16137994
39 PIK3CA NM_006218.4(PIK3CA):c.317G>T (p.Gly106Val) SNV Likely Pathogenic
376479 rs1057519930 GRCh37: 3:178916930-178916930
GRCh38: 3:179199142-179199142
40 CDKN2A NM_000077.5(CDKN2A):c.340C>A (p.Pro114Thr) SNV Likely Pathogenic
376382 rs104894104 GRCh37: 9:21971018-21971018
GRCh38: 9:21971019-21971019
41 CDKN2A NM_000077.5(CDKN2A):c.341C>A (p.Pro114His) SNV Likely Pathogenic
376383 rs121913386 GRCh37: 9:21971017-21971017
GRCh38: 9:21971018-21971018
42 PIK3CA NM_006218.4(PIK3CA):c.452T>C (p.Val151Ala) SNV Likely Pathogenic
873163 rs1724363237 GRCh37: 3:178917577-178917577
GRCh38: 3:179199789-179199789
43 ALK NM_004304.5(ALK):c.4472A>G (p.Lys1491Arg) SNV Likely Pathogenic
133474 rs1881420 GRCh37: 2:29416481-29416481
GRCh38: 2:29193615-29193615
44 ALK NM_004304.5(ALK):c.4587C>G (p.Asp1529Glu) SNV Likely Pathogenic
133476 rs1881421 GRCh37: 2:29416366-29416366
GRCh38: 2:29193500-29193500
45 CDKN2A NM_000077.5(CDKN2A):c.47_50del (p.Leu16fs) MICROSAT Likely Pathogenic
142061 rs587782206 GRCh37: 9:21974777-21974780
GRCh38: 9:21974778-21974781
46 CDKN2A NM_000077.5(CDKN2A):c.292C>T (p.His98Tyr) SNV Likely Pathogenic
419560 rs1064793953 GRCh37: 9:21971066-21971066
GRCh38: 9:21971067-21971067
47 ALK NM_004304.5(ALK):c.4381A>G (p.Ile1461Val) SNV Likely Pathogenic
133472 rs1670283 GRCh37: 2:29416572-29416572
GRCh38: 2:29193706-29193706
48 TP53 NM_000546.6(TP53):c.488A>G (p.Tyr163Cys) SNV Likely Pathogenic
127814 rs148924904 GRCh37: 17:7578442-7578442
GRCh38: 17:7675124-7675124
49 TP53 NM_000546.6(TP53):c.844C>T (p.Arg282Trp) SNV Likely Pathogenic
12364 rs28934574 GRCh37: 17:7577094-7577094
GRCh38: 17:7673776-7673776
50 TP53 NM_000546.6(TP53):c.724T>A (p.Cys242Ser) SNV Likely Pathogenic
376579 rs1057519982 GRCh37: 17:7577557-7577557
GRCh38: 17:7674239-7674239

Cosmic variations for Lung Squamous Cell Carcinoma:

8 (show top 50) (show all 14419)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM101712070 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.3171G>C p.V1057= 2:135200405-135200405 13
2 COSM131775319 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1815G>C p.V605= 2:135200405-135200405 13
3 COSM87596300 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.3177G>C p.V1059= 2:135200405-135200405 13
4 COSM142228089 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1566G>C p.V522= 2:135200405-135200405 13
5 COSM142168947 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.-18G>C p.? 7:89218278-89218278 13
6 COSM92052275 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1662G>T p.L554F 7:89334644-89334644 13
7 COSM142179137 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3235C>T p.Q1079* 7:89336466-89336466 13
8 COSM142183562 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1361A>G p.K454R 7:89334592-89334592 13
9 COSM142180477 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1413G>T p.L471F 7:89334644-89334644 13
10 COSM142169111 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.494G>A p.C165Y 7:89333725-89333725 13
11 COSM142178407 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.734A>G p.N245S 7:89333965-89333965 13
12 COSM92062218 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.1610A>G p.K537R 7:89334592-89334592 13
13 COSM92044981 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.983A>G p.N328S 7:89333965-89333965 13
14 COSM92017258 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.743G>A p.C248Y 7:89333725-89333725 13
15 COSM92016873 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.232G>C p.D78H 7:89218278-89218278 13
16 COSM92047471 ZNF804B lung,NS,carcinoma,squamous cell carcinoma c.3484C>T p.Q1162* 7:89336466-89336466 13
17 COSM88573896 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.163G>T p.A55S 2:184866420-184866420 13
18 COSM143615263 ZNF804A lung,NS,carcinoma,squamous cell carcinoma c.-93G>T p.? 2:184866420-184866420 13
19 COSM135196993 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.386G>A p.R129H 16:2002647-2002647 13
20 COSM137961812 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.386G>A p.R129H 16:2002647-2002647 13
21 COSM94776745 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 13
22 COSM131483085 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.934T>A p.C312S 18:25226984-25226984 13
23 COSM140721616 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.757C>T p.P253S 18:25226501-25226501 13
24 COSM94799739 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 13
25 COSM131506553 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.1417C>T p.P473S 18:25226501-25226501 13
26 COSM140704568 ZNF521 lung,NS,carcinoma,squamous cell carcinoma c.274T>A p.C92S 18:25226984-25226984 13
27 COSM89756750 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 13
28 COSM144163369 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.779+33G>T p.? 7:57120351-57120351 13
29 COSM90068315 ZNF479 lung,NS,carcinoma,squamous cell carcinoma c.1064G>T p.C355F 7:57120351-57120351 13
30 COSM106286350 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 13
31 COSM112397402 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 13
32 COSM123216142 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 13
33 COSM125618139 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 13
34 COSM124797288 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 13
35 COSM122109165 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 13
36 COSM86289413 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 13
37 COSM124886437 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36= 19:53571702-53571702 13
38 COSM101607526 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 13
39 COSM101586020 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 13
40 COSM143104196 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 13:20006558-20006558 13
41 COSM120263221 ZIC4 lung,NS,carcinoma,squamous cell carcinoma c.597G>A p.T199= 3:147395943-147395943 13
42 COSM129142258 ZIC4 lung,NS,carcinoma,squamous cell carcinoma c.747G>A p.T249= 3:147395943-147395943 13
43 COSM85617592 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.138C>T p.A46= 3:147410250-147410250 13
44 COSM85619505 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.99G>T p.V33= 3:147410211-147410211 13
45 COSM85617600 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.587G>A p.G196D 3:147410699-147410699 13
46 COSM85618817 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.244C>T p.H82Y 3:147410356-147410356 13
47 COSM85617734 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.430C>G p.P144A 3:147410542-147410542 13
48 COSM85619514 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.979A>T p.T327S 3:147411091-147411091 13
49 COSM85618249 ZIC1 lung,NS,carcinoma,squamous cell carcinoma c.64C>A p.H22N 3:147410176-147410176 13
50 COSM125185026 ZFHX4 lung,NS,carcinoma,squamous cell carcinoma c.2841G>T p.L947= 8:76707874-76707874 13

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

6 (show top 50) (show all 61)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain EMC10 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain GARIN5A Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss CD44 Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP63 Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.91 TP53 PIK3CA KRAS HRAS EGFR
2
Show member pathways
12.66 EGFR HRAS KRAS PIK3CA TP53
3
Show member pathways
12.6 TP53 PIK3CA KRAS HRAS EGFR
4
Show member pathways
12.54 EGFR HRAS KRAS PIK3CA TP53
5
Show member pathways
12.39 PIK3CA KRAS HRAS EGFR
6
Show member pathways
12.37 PIK3CA KRAS HRAS EGFR
7 12.35 TP53 KRAS HRAS EGFR
8
Show member pathways
12.34 TP53 PIK3CA KRAS HRAS EGFR
9
Show member pathways
12.27 TP53 PIK3CA KRAS HRAS EGFR
10
Show member pathways
12.21 EGFR HRAS KRAS PIK3CA TP53
11 12.2 PIK3CA KRAS HRAS EGFR
12
Show member pathways
12.19 PIK3CA KRAS HRAS EGFR
13
Show member pathways
12.14 EGFR HRAS KRAS PIK3CA TP53
14 12.13 TP53 PIK3CA KRAS HRAS
15
Show member pathways
12.03 PIK3CA KRAS HRAS EGFR
16
Show member pathways
12.01 PIK3CA KRAS HRAS EGFR
17
Show member pathways
11.97 PIK3CA KRAS HRAS EGFR
18 11.9 PIK3CA KRAS HRAS EGFR
19
Show member pathways
11.89 PIK3CA KRAS HRAS EGFR
20
Show member pathways
11.87 PIK3CA KRAS HRAS
21
Show member pathways
11.84 HRAS KRAS PIK3CA
22
Show member pathways
11.82 PIK3CA KRAS HRAS
23
Show member pathways
11.8 PIK3CA KRAS HRAS
24 11.77 TP53 PIK3CA HRAS
25 11.74 KRAS NFE2L2 TP53
26
Show member pathways
11.74 HRAS KRAS PIK3CA
27
Show member pathways
11.71 PIK3CA KRAS HRAS
28 11.71 TP53 PIK3CA KRAS HRAS
29
Show member pathways
11.66 PIK3CA KRAS HRAS EGFR
30 11.62 TP53 PIK3CA HRAS
31
Show member pathways
11.61 PIK3CA KRAS HRAS
32 11.58 KRAS HRAS EGFR
33
Show member pathways
11.52 PIK3CA KRAS HRAS
34
Show member pathways
11.46 TP53 PIK3CA KRAS HRAS
35 11.43 KRAS HRAS EGFR
36 11.36 PIK3CA KRAS HRAS
37 11.34 PIK3CA HRAS EGFR
38 11.22 PIK3CA KRAS HRAS
39 11.15 KRAS HRAS EGFR
40 11.15 TP53 KRAS HRAS EGFR
41
Show member pathways
11.1 EGFR HRAS KRAS
42 11.08 EGFR KRAS PIK3CA
43 11.06 TP53 KRAS HRAS EGFR
44 10.96 TP53 PIK3CA NFE2L2 KRAS HRAS EGFR
45 10.87 HRAS EGFR
46
Show member pathways
10.76 KRAS HRAS
47 10.73 NFE2L2 KRAS HRAS EGFR
48 10.67 PIK3CA EGFR

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.26 TP53 NFE2L2
2 positive regulation of miRNA maturation GO:1903800 9.16 TP53 EGFR
3 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 8.92 TP53 NFE2L2

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activator activity GO:0043539 8.8 PIK3CA KRAS HRAS

Sources for Lung Squamous Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....